Business Context and Reporting Period
Pulse Biosciences, Inc. (PLSE) is a novel ablation company developing medical devices based on its patented Nano-pulse Stimulation (NPS) technology. The company has shifted its primary focus from dermatology to cardiology (specifically atrial fibrillation) and soft tissue ablation. This Form 10-Q covers the quarterly period ended September 30, 2025.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 |
|---|---|---|
| Product Revenue | $86,000 | $86,000 |
| Net Loss | $(19,385,000) | $(55,348,000) |
| Loss Per Share (Basic & Diluted) | $(0.29) | $(0.82) |
| Research & Development Expenses | $11,393,000 | $33,794,000 |
| Selling, General & Administrative Expenses | $8,781,000 | $24,699,000 |
| Stock-Based Compensation | $5,617,000 | $16,487,000 |
| Cash and Cash Equivalents (Sept 30, 2025) | $95,214,000 | |
| Net Cash Used in Operating Activities (9 Months) | $(39,367,000) | |
| Net Cash Provided by Financing Activities (9 Months) | $16,773,000 |
Material Changes vs. Prior Period
- Revenue Generation: The company recorded $86,000 in product revenue for the three and nine months ended September 30, 2025, compared to zero revenue in the same periods of 2024. This marks the commencement of commercial sales for the Vybrance Percutaneous Electrode System.
- Expense Growth: Total operating expenses increased significantly. R&D expenses rose by $3.7 million (quarterly) and $12.1 million (year-to-date) compared to 2024, driven by increased paid services, external research, and stock-based compensation. SG&A expenses increased by $2.8 million (quarterly) and $10.4 million (year-to-date), primarily due to higher stock-based compensation and personnel costs.
- Stock-Based Compensation: Stock-based compensation expense more than doubled year-over-year, increasing from $2.98 million to $5.62 million for the quarter, and from $6.79 million to $16.49 million for the nine-month period.
- Warrant Exercises: During the nine months ended September 30, 2025, the company received $14.1 million in gross proceeds from the exercise of warrants related to the 2024 Rights Offering.
Guidance, Outlook, and Risks
- Commercialization: The company has initiated a clinical trial (PRECISE BTN) for the Vybrance Percutaneous Electrode System to treat benign thyroid nodules, with enrollment expected to complete in Q1 2026. Over 200 patient procedures have been completed to date across pilot programs and trials.
- Cardiac Pipeline: The company is advancing its nPulse Cardiac Surgical Clamp and nPulse 360 Cardiac Catheter for the treatment of atrial fibrillation. The cardiac clamp has received FDA Breakthrough Device Designation and an IDE for a pivotal trial. The cardiac catheter IDE submission is pending, with a study expected to commence in Q1 2026.
- Liquidity: Management believes existing cash of $95.2 million is sufficient to fund operations for at least the next twelve months. However, the company anticipates needing additional capital to fully fund operations and commercialization efforts.
- Risks: Key risks include the need for additional financing, the uncertainty of clinical trial outcomes, regulatory approval timelines (PMA vs. 510(k)), and the company's dependence on a single platform technology (NPS). The company also notes that performance-based stock options granted in 2025 are not currently probable of being achieved, resulting in no expense recognition for those specific awards.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $95.2 million cash balance against the current operating cash burn of approximately $39.4 million per nine months.
- Revenue Scalability: Assess the trajectory of the $86,000 in initial revenue to determine if it can scale to offset the high operating costs (approx. $20.5 million per quarter).
- Stock-Based Compensation: Review the impact of the $16.5 million in stock-based compensation on future dilution and expense recognition, particularly regarding the market-based and performance-based options.
- Regulatory Milestones: Monitor the status of the IDE for the cardiac catheter and the enrollment progress of the PRECISE BTN trial, as these are critical for future revenue streams.
- Major Shareholder Influence: Note that Co-Chairman Robert W. Duggan owns approximately 72% of the voting power and purchased 88% of the 2024 Rights Offering units, which may impact future capital raising dynamics.